Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

© 2018 Elsevier Inc. Purpose: To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for =24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM). Methods...

Full description

Bibliographic Details
Main Authors: Kong, X., Nguyen, N., Choi, Y., Zhang, Guicheng, Nguyen, H., Filka, E., Green, S., Yong, W., Liau, L., Green, R., Kaprealian, T., Pope, W., Nghiemphu, P., Cloughesy, T., Lassman, A., Lai, A.
Format: Journal Article
Published: Elsevier Inc. 2018
Online Access:http://hdl.handle.net/20.500.11937/74158

Similar Items

Similar Items